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Abstract
Background: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by cyst formation
throughout the kidney parenchyma. It is caused by mutations in either of two genes, PKD1 and PKD2. Mice that
lack functional Pkd1 (Pkd1
-/-), develop rapidly progressive cystic disease during embryogenesis, and serve as a
model to study human ADPKD. Genome wide transcriptome reprogramming and the possible roles of micro-RNAs
(miRNAs) that affect the initiation and progression of cyst formation in the Pkd1
-/- have yet to be studied. miRNAs
are small, regulatory non-coding RNAs, implicated in a wide spectrum of biological processes. Their expression
levels are altered in several diseases including kidney cancer, diabetic nephropathy and PKD.
Results: We examined the molecular pathways that modulate renal cyst formation and growth in the Pkd1
-/- model by
performing global gene-expression profiling in embryonic kidneys at days 14.5 and 17.5. Gene Ontology and gene set
enrichment analysis were used to identify overrepresented signaling pathways in Pkd1
-/- kidneys. We found
dysregulation of developmental, metabolic, and signaling pathways (e.g. Wnt, calcium, TGF-b and MAPK) in Pkd1
-/-
kidneys. Using a comparative transcriptomics approach, we determined similarities and differences with human ADPKD:
~50% overlap at the pathway level among the mis-regulated pathways was observed. By using computational
approaches (TargetScan, miRanda, microT and miRDB), we then predicted miRNAs that were suggested to target the
differentially expressed mRNAs. Differential expressions of 9 candidate miRNAs, miRs-10a, -30a-5p, -96, -126-5p, -182,
-200a, -204, -429 and -488, and 16 genes were confirmed by qPCR. In addition, 14 candidate miRNA:mRNA reciprocal
interactions were predicted. Several of the highly regulated genes and pathways were predicted as targets of miRNAs.
Conclusions: We have described global transcriptional reprogramming during the progression of PKD in the
Pkd1
-/- model. We propose a model for the cascade of signaling events involved in cyst formation and growth. Our
results suggest that several miRNAs may be involved in regulating signaling pathways in ADPKD. We further
describe novel putative miRNA:mRNA signatures in ADPKD, which will provide additional insights into the
pathogenesis of this common genetic disease in humans.
Background
Autosomal dominant polycystic kidney disease (ADPKD)
is characterized by fluid-filled cysts that are thought to
result from abnormal cell proliferation and deregulated
apoptosis, increased secretion of fluids into the tubular
lumen, irregular cell-matrix interactions, and defective
cellular polarity [1,2]. Thus, normal parenchyma is
replaced by a cystic epithelium and fibrotic tissue [3].
Genetic mutations in PKD1 (encoding polycystin 1; PC-
1) are responsible for majority of cases of ADPKD, the
remainder are due to loss of PKD2 (encoding polycystin
2; PC-2). Loss of PC-1 or PC2 expression results in dis-
ruption of intracellular Ca
2+ levels, which may lead to
abnormal proliferation of tubule epithelial cells [4-7].
Additionally, the involvement of PC-1 in various path-
ways related to proliferation, such as G-protein
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any medium, provided the original work is properly cited.signaling, Wnt signaling, AP-1, and cell cycle arrest has
been reported [8-12]. However, the manner in which
these diverse pathways are integrated into cellular cir-
cuitry and regulated during progression of ADPKD is
not well studied.
MicroRNAs (miRNAs) are small endogenous non-
protein encoding RNAs that post-transcriptionally modu-
late gene expression by binding to the 3’UTR of target
mRNAs [13]. They are involved in many biological pro-
cesses including cell differentiation, cell proliferation, cell
mobility and apoptosis [14] and are associated with many
diseases including cancer, hypertension, diabetes, and kid-
ney dysfunction [15]. For example, Kato et al reported a
role for miR-192 in diabetic nephropathy [16]. Also, over-
expression of the miR-17-92 cluster may play a role in
renal cell carcinoma [17]. Further, the importance of miR-
NAs that are expressed in kidney is supported by mouse
knockout studies [18-21]. For example, eliminating Dicer,
a key enzyme in miRNA biogenesis, from podocytes, a cell
type required for the formation of the size exclusion
barrier in the glomerulus, results in progressive loss of
podocyte function [20,21]. Some studies have also sug-
gested a role for miRNAs in ADPKD [22-24].
The Pkd1
-/- mouse model develops cystic disease caused
by mutation of the same gene responsible for the majority
of human ADPKD, and provides a system to study the
pathogenesis of ADPKD [25]. However, a systematic,
large-scale study, elucidating global changes in gene
expression during disease progression in the Pkd1
-/-
mouse model has yet to be reported. Using the Pkd1
-/-
model to study the pathogenesis of ADPKD offers the abil-
ity to compare gene expression in pre-diseased and dis-
eased kidneys. In the current investigation, we (1) use the
Pkd1
-/- model to explore the transcriptional changes that
occur in ADPKD on a whole genome scale, (2) undertake
a comparative transcriptomics approach to determine
similarities and differences with human ADPKD, and (3)
investigate whether these changes might be related to
changes in miRNA expression. We systemically predicted
the possible miRNAs that may be associated with the
changes in mRNA expression levels during disease
progression that were determined by gene expression
microarray analysis. We predicted miRNAs that could tar-
get signaling pathways in ADPKD. Our results suggest
that several miRNAs may be involved in regulating the
genetic switches in ADPKD. We further describe several
miRNAs and putative miRNA-mRNA signatures, which
were previously not reported in ADPKD.
Methods
Animal Model
Kidneys from wild type (WT; Pkd1
+/+)a n dPkd1-null,
designated as Pkd1
-/-, mutant littermates were investi-
gated at the embryonic ages 14 (E14.5) and 17 (E17.5).
The kidneys were fixed in 4% paraformaldehyde over-
night, paraffin-embedded, and stained with hematoxylin
and eosin. The sections were visualized with a Nikon
Eclipse 80i microscope and photographed with a Qima-
ging Retiga 2000R Fast 1394 camera using NIS-Elements
Basic Research 2.34 software (Micro Video Instruments,
Avon, MA).
Total RNA extraction and Microarrays
Total RNA was extracted from embryonic kidneys at,
E14.5 and E17.5, using the Qiagen miRNeasy Mini kit
(Qiagen, Valencia, CA). Three pairs of kidneys at E14.5
and E17.5 were processed. Each pair was analyzed sepa-
rately. The integrity and purity of the mRNA samples
were assessed prior to hybridization using Bioanalyser
2100 with mRNA Nanochips (Agilent Technologies).
RNA hybridization was performed, and gene expression
profiles were determined using Illumina Mouse Sentrix
6 version 2 Beadchips. The data extraction was per-
formed by using an Illumina Bead Studio V3.1.3.0 soft-
ware with the output being raw, non-normalized bead
summary values.
The raw data matrix extracted from Beadstudio was
uploaded in Bioconductor R version 2.9.1 for down-
stream analysis. The raw data were read using the bea-
darray package available through the Bioconductor
project. The raw intensities were background adjusted
by the Subtract method. The log2 summarized data
were quantile normalized. The limma package [26] with
empirical Bayes method was used to assess the differen-
tially expressed genes.
The data discussed in this publication have been
deposited in NCBI’s Gene Expression Omnibus (GEO)
and are accessible through GEO Series accession num-
ber GSE24352 (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE24352).
Gene set enrichment analysis and Gene Ontology
enrichment analysis
G e n es e te n r i c h m e n ta n a l y s i s( G S E A )( h t t p : / / w w w .
broad.mit.edu/gsea/) was used to identify potential gene
pathways and key transcription factors (TFs) that may
modulate cystogenesis (Figure 1). The GSEA C2 data-
base (curated gene sets from BioCarta, KEGG, Signaling
Pathway database, Signaling Gateway, Signal Transduc-
tion Knowledge Environment, Human Protein Reference
database, GenMAPP, Sigma-Aldrich Pathways, Gene
Arrays, BioScience Corp., Human Cancer Genome
Anatomy Consortium database) that includes well-stu-
died metabolic and signaling pathways and published
microarray data sets was used for pathway analysis. The
GSEA C3 database containing shared and evolutionarily
conserved TF binding motifs defined by the TRANSFAC
database was used for TF analysis. The description of
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natures Database website: http://www.broad.mit.edu/
gsea/msigdb/index.jsp Enrichment of Gene Ontology
(GO) categories (Figure 1) in the differentially expressed
genes was determined using Bioconductor’s GOstats
package [27] for both up- and down-regulated genes.
Comparison with other datasets on ADPKD
Two datasets on ADPKD with mutation in Pkd1,
Pkd1
L3/L3 [28] and human ADPKD [29] were obtained
from the GEO database (http://www.ncbi.nlm.nih.gov/
geo/; [30]). Raw data were log2 summarized and quan-
tile normalized. The limma package [26] with empirical
Bayes method was used to assess the differentially
expressed genes between mutants and controls. These
were compared with the differentially expressed genes
obtained in comparisons using custom written Perl
scripts.
miRNA prediction
As shown in Figure 1, a combinatorial strategy was used
where target miRNAs were predicted for the differen-
tially expressed genes using four algorithms, TargetScan
(http://www.targetscan.org/; [31]), miRanda (http://www.
microrna.org/; [32]), miRDB (http://mirdb.org/miRDB/;
[33]) and microT (http://diana.cslab.ece.ntua.gr/microT/;
Experimental design
WT vs Pkd1-/- at E14.5, WT vs Pkd1-/- at E17.5, E14.5 vs E17.5 for Pkd1-/-
Differentially expressed (DE) genes for each comparison 
Gene Ontology classification Gene Set Enrichment Analysis
Enriched gene-
sets/pathways
Overrepresented
Transcription Factor
promoter binding motifs
Pathways/gene sets related
to Polycystic Kidney Disease
(PKD)
miRNA target prediction
using miRanda, miRDB,
TargetScan and microT
Predicted miRNAs target genes in
PKD related pathways/gene-sets
Verification of candidate
genes by qPCR
miRNAs-expression
analysis by miRNA-qPCR
Comparison with data sets on PKD in GEO database
Figure 1 Schematic representation of combinatorial approach identifying genes, molecular pathways and target miRNAs in ADPKD.
mRNA expression profilings at E14.5 and E17.5 were analysed by limma package in Bioconductor R. Differentially expressed (DE) genes were
obtained for comparisons- Mutant vs. WT at E14.5, at E17.5 and E14.5 vs E17.5 for mutants. Gene Ontology (GO) was used to compare the
dominant biological processes in mutant and WT at each time point. Gene set enrichment analysis (GSEA) was performed to identify gene
pathways associated with PKD progression and renal cyst growth; and to search for overrepresented TF promoter binding motifs among DE
genes. Target miRNAs for DE genes at each comparison were predicted using TargetScan, miRanda, miRDB and microT and results were
overlapped using Perl scripts. A subset of DE genes associated with PKD (as revealed from GO and GSEA analysis) and targeted by miRNAs
(revealed by target prediction tools), was selected for verification by qPCR. miRNAs predicted to target DE genes by atleast two tools, were
selected for verification by qPCR. Additionally, comparison of DE genes with other data sets on ADPKD were performed to derive set of
pathways core to ADPKD.
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two or more algorithms, results were intersected (Addi-
tional file 1) using custom written Perl scripts (Addi-
tional file 2).
Quantitative real-time PCR
Total RNA was extracted from Pkd1
-/- and WT kidneys.
Three independent biological replicates (different from
those used for microarrays) were used and all reactions
were run in duplicates for all the expression analysis of
genes and miRNAs. For all the quantitative real-time-
PCR (qPCR) assays, the ABI PRISM 7300 Sequence
Detection System was used. The comparative CT
method was used to obtain relative quantitation of
genes and miRNAs as per the manufacturer’sp r o t o c o l
(Qiagen). For gene expression analysis, cDNA was made
using Superscript III reverse transcriptase (Invitrogen).
qPCRs were performed, using Power SYBR
® Green PCR
Master Mix (Invitrogen). Primer sets for P2rx7, Cpeb3,
Hdac9, Sox6, Ltbp1, Calcr, Pitx2, Fgfr3, Fgf10, Adam22,
Ddx3y, F2rl2, Grap2, Edil3, Mysm1, Alg6 and Alg8 are
available in Additional file 3. 18S rRNA was used as the
endogenous control.
miRNA reverse transcription was performed using the
TaqMan microRNA Reverse Transcription Kit and
miRNA-specific primers (Applied Biosystems, Foster
City, CA). Real-time TaqMan miRNA-assays were used
to quantify miRNA expression using the TaqMan
Master Mix and validated primer/probe sets (Applied
Biosystems). miRNA levels were normalized to snoRNA-
202. Cycling conditions for TaqMan PCR consisted of
an initial incubation at 50°C for 2 min and 95°C for 15
sec and 60°C for 1 min.
Results
Pkd1
-/- mice model and design of experiment
To study the detailed changes in molecular profiles dur-
ing the progression of ADPKD, we generated and com-
pared gene expression profiles of Pkd1
-/- embryonic
kidneys and age-matched WT kidneys at two stages,
E14.5 and E17.5 (Figure 1; Additional file 4). Pkd1
-/-
embryos develop rapidly progressive kidney cysts during
embryogenesis, with null mutant kidneys showing no
cysts at E14.5 and marked cystic changes by E17.5
(Figure 2). Unsupervised hierarchical clustering was able
to discriminate WT and mutant kidney samples at both
time points (Figure 3). At the same time, the cluster ana-
lysis was also able to distinguish changes between E14.5
and E17.5 kidneys (Figure 3). Table 1 shows a summary
of number of differentially expressed genes and pathways
for all of the comparisons. Genes showing a greater than
2-fold difference in expression between WT and mutant
kidneys at E14.5 as well as at E17.5 (empirical Bayes
moderated t-statistic, unequal variance, uncorrected
p-value ≤0.05), were considered to be differentially
expressed whereas in the comparisons of WT kidneys at
E14.5 vs E17.5 and Pkd1
-/- kidneys at E14.5 vs E17.5,
genes with ≥ 2-fold difference in expression at p-value
≤0.05 (corrected for multiple testing by Benjamini-Hoch-
berg method) were considered as differentially expressed.
The expression of 454 genes was significantly changed
between WT and mutant kidneys at E14.5 (Table 1,
Additional file 5) whereas 884 genes were significantly
changed at E17.5 between WT and mutant kidneys
(Table 1, Additional file 6). The comparison of E14.5 and
E17.5 WT kidneys yielded 1189 differentially expressed
genes (Additional file 7) whereas 2287 genes were differ-
entially expressed in comparison of Pkd1
-/- kidneys at
E14.5 vs E17.5 (Table 1, Additional file 8). Comparing
differentially expressed genes observed in Pkd1
-/- at E14.5
vs E17.5 (2287 genes) and in WT at E14.5 vs E17.5 (1189
genes) identified genes that were specifically changing
during development in diseased (Additional file 9)
or healthy conditions (Additional file 10) as shown in
Figure 4. This comparison also indicated genes that were
regulated during aging from E14.5 to E17.5 regardless of
the genotype (Figure 4; Additional file 11). These results
indicate that maturation accounted for the greatest num-
ber of changes in gene expression, more so than the cyst
formation. Nevertheless, 1397 genes (Additional file 9)
could be identified for which changes in gene expression
levels were specific for Pkd1
-/- kidneys. Thus, this analysis
served to identify a set of genes specifically changing in
PKD that can yield insights about the regulation of gene
expression during cystogenesis.
E17.5
E14.5
Pkd1 WT Pkd1-/-
Figure 2 Pathology of Pkd1
-/- mouse model at embryonic ages:
E14.5 and E17.5. At E14.5 the mutant and WT kidneys are similar.
Kidney development in Pkd1
-/- mutants appears to proceed
normally until E15.5. By E17.5, the kidneys of Pkd1
-/- mutants are
filled with many large numbers of renal cysts. The rate of cyst
development indicates aggressive disease in Pkd1
-/- mutants.
Hematoxylin/Eosin stained; Scale bar 20x.
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-/- mutants at
E14.5 and E17.5
At E14.5, Pkd1
-/- mutants do not exhibit any cyst formation
(Figure 2). Therefore gene expression changes at E14.5 may
provide an indication of signaling pathways that cause cysts
rather than being a consequence of cyst formation. Among
the most interesting genes identified by microarrays were
P2rx7, Cer1, Frzb, Wnt7b, Dvl3, Gpr34, and Gpr116.
These genes are representative of calcium, Wnt and GPCR
signaling, and their roles are discussed later.
Pkd1
-/- mutant embryos show numerous large renal
cysts at E17.5. Microarray analysis showed up-regulation
E14.5 Pkd1-/-
vs WT
E17.5 Pkd1-/-
vs WT
E14.5 Pkd1-/- vs
E17.5 Pkd1-/-
E14.5 WT vs
E17.5 WT
Figure 3 Differential expression of gene in PKD and control animals. Heatmap was produced using simultaneous clustering of rows and
columns of the data matrix using complete linkage algorithm and a euclidean distance metric. Prior to clustering, values were transformed to
zero (row-wise) mean and unit (row-wise) variance. The gene clustering tree is shown on the left and the sample clustering tree is shown on
the top. The samples are clustering broadly into two groups, wild type (WT) and PKD. The color scale shown at the right illustrates the relative
expression level of the indicated gene across all samples: red denotes expression > 0 and green denotes an expression < 0. Genes shown here
are from mRNA microarrays.
Table 1 Summary of all the analyses
Mutant vs WT at
E14.5
Mutant vs WT at
E17.5
E17.5 Mutant vs E14.5
Mutant
1 Differentially expressed genes Up-regulated in mutant 228 512 1284
Down-regulated in mutant 226 372 1003
2 GO categories (Biological Processes)
enrichment
Up-regulated in mutant 189 362 91
Down-regulated in mutant 157 271 42
3 a) Curated pathways Up-regulated in mutant 46 52 31
Down-regulated in mutant 68 23 22
b) Enriched TFs Up-regulated in mutant 31 35 12
Down-regulated in mutant 29 18 6
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Grem1, Mmp12, Sema3c, Sema4c and Sema6c and tran-
scription factors (TFs)- Gli2, Foxo1, Foxp2, Hoxb8,
Pou2f1 and Zbtb32 at E17.5 in Pkd1
-/- mutant kidneys
compared to WT. Many of these genes are essential for
ureteric bud formation, outgrowth, and branching dur-
ing kidney development. On the other hand, the expres-
sion of genes associated with the differentiation of
specific nephron segments, such as Umod, Pck1, Fmo2,
Slc12a3, Pvalb, and Angpt2 were down-regulated in the
null mutants. These data suggest that Pkd1
-/- mutants
have failed to maintain nephron segment-specific tran-
scriptional signatures. Additionally, we found changes in
expression of genes previously related to cyst growth
and progression such as components of MAPK and
JAK/STAT signaling (these are detailed later in the fol-
lowing sections).
Gene pathway analysis using GO term enrichment and
Gene Set Enrichment Analysis
Gene Ontology (GO) and Gene Set Enrichment Analysis
(GSEA; http://www.broad.mit.edu/gsea/) are two bioin-
formatics approaches to identify pathways involved in
specific biological processes such as development and
disease. GO term enrichment uses association of Gene
Ontology terms to genes in a selected gene list. This
method discovers what a set of genes may have in com-
mon by examining annotations and finding significant
Higher at E17.5
E14.5 vs E17.5 WT E14.5 vs E17.5 Pkd1-/-
Genes change with aging
from E14.5 to E17.5
Higher at E14.5
Genes that
specifically change
during disease
Genes whose
regulation is lost in
PKD
700 170
302
129 697
588
E14.5 vs E17.5 WT E14.5 vs E17.5 Pkd1-/-
Figure 4 Genes specific to aging and transition under healthy and diseased conditions. Venn diagram shows genes that are specific to
transition under healthy and diseased conditions as well as genes changing with aging from the embryonic age 14 to 17. The red circles show
genes changing only in mutants and green circles show genes changing only in wild-types. The overlapped from both the comparisons yielded
genes changing with aging and common to both mutants and wild-types.
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known set of genes shows statistically significant, con-
cordant differences between two biological conditions,
e.g. WT and Pkd1
-/-.
Table 2 and Additional file 12 show the number of
enriched GO terms associated with up- and down-regu-
lated genes for each comparison. Of the 1892 gene sets
tested in GSEA, we found that 117 (46 up- and 71
down-regulated) pathways at E14.5 and 75 (52 up- and
23 down-regulated) pathways at E17.5 were dysregulated
in the mutants. We defined overrepresented pathways
by a nominal (NOM) p-value ≤ 0.05. Table 3 and Addi-
tional file 13 show enriched gene sets in mutants for
up- and down-regulated genes at E14.5 and E17.5. Some
pathways may be represented by multiple independent
gene sets.
We found that most of the down-regulated gene sets in
Pkd1
-/- mutants compared to WT at E14.5 and E17.5
represent metabolic pathways (Table 3 and Additional
file 13), as suggested by GSEA and GO analysis. In con-
trast, both the GSEA and GO analysis of up-regulated
gene sets in Pkd1
-/- mutants compared to WT at E14.5
a n dE 1 7 . 5s u g g e s t e dt h a tPkd1
-/- mutants displayed a
rich gene transcriptional profile for kidney development
and regeneration, including Wnt, calcium, MAPK and
TGFb signaling (Additional file 13). Among the path-
ways identified by GO and GSEA were the following:
Activation of mitogenic signaling pathways
We identified 11 up-regulated gene sets in Pkd1
-/-
mutants compared to WT associated with mitogenic
signaling at E17.5, including those associated with
growth factor/receptor tyrosine kinase (RTK) signaling
(e.g. FGFs, EGF) and extracellular cellular matrix
(ECM)/integrin signaling. Previous studies have sug-
gested that activation of EGFs, FGFs and their receptors
could promote tubular epithelial cell proliferation and
cyst formation in PKD [35-37]. We found Fgfr1 (3.10
fold), Fgfr3 (10.16 fold), Fgf10 (4.18 fold), Nrg1 (3.37
fold) and Prkcb (2.56 fold) up-regulated in Pkd1
-/-
mutants compared to WT at E17.5. Although gene sets
associated with G protein-coupled receptor (GPCR)
were not definitively enriched (p = 0.07) in the cystic
Table 2 GO category enrichment: Biological Processes - overrepresented
Mutant at E14.5 Mutant at E17.5
Up-regulated
Establishment or maintenance of apical/basal cell polarity Calcium-mediated signaling
Vesicle localization Programmed cell death
Cytosolic calcium ion transport Negative regulation of transcription
Calcium ion transport into cytosol Cell development
Blood vessel development Cell motion
Vasculature development Apoptosis
Tube development Notch signaling pathway
Renal water transport Cell cycle arrest
cAMP catabolic process Transforming growth factor beta receptor signaling pathway
Fibroblast growth factor receptor signaling pathway Regulation of cell-cell adhesion
Renal system process involved in regulation of blood volume Kidney development
Production of nitric oxide during acute inflammatory response Cell migration
Extracellular matrix organization Fluid transport
Vasopressin secretion Extracellular polysaccharide biosynthetic process
Proteolysis Wnt receptor signaling pathway
Cell-cell adhesion mediated by integrin
Fibroblast growth factor receptor signaling pathway
Down-regulated
Wnt receptor signaling pathway, calcium modulating pathway Positive regulation of cytokine secretion
Cell-cell signaling Positive regulation of gene expression
G1/S transition of mitotic cell cycle Positive regulation of MAP kinase activity
Carbon metabolism Metabolic processes
Glycolysis Cell motility
Amino acid metabolism Developmental process
RNA splicing DNA replication
Positive regulation of cell division Antigen processing
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-/- animals
a) E14.5
Up-regulated NES
HSA04630_JAK_STAT_SIGNALING_PATHWAY JAK-STAT Pathway 1.34
NGUYEN_KERATO_DN Notch Signaling 1.32
HSA04920_ADIPOCYTOKINE_SIGNALING_PATHWAY Adipocytokine Signaling 1.3
HSA04210_APOPTOSIS Apoptosis 1.13
WNT_TARGETS Wnt Signaling 1.43
PARP_KO_UP Genomic Integrity 1.27
RACCYCDPATHWAY Cell Cycle 1.2
REN_E2F1_TARGETS Cell Cycle 1.19
Down-regulated
LYSINE_DEGRADATION Amino Acid Metabolism -1.76
PROPANOATE_METABOLISM Carbohydrate Metabolism -1.64
CROONQUIST_IL6_RAS_DN JAK-STAT Pathway -1.44
YU_CMYC_UP Myc regulated genes -1.37
HSA00330_ARGININE_AND_PROLINE_METABOLISM Amino Acid Metabolism -1.27
HSA00620_PYRUVATE_METABOLISM Carbohydrate Metabolism -1.25
GLUCONEOGENESIS Carbohydrate Metabolism -1.21
GLYCOLYSIS Carbohydrate Metabolism -1.21
CELL_ADHESION_RECEPTOR_ACTIVITY Cell Adhesion -1.17
BETA_ALANINE_METABOLISM Amino Acid Metabolism -1.17
LEE_MYC_E2F1_DN Myc regulated genes -1.16
KERATINOCYTEPATHWAY Mitogenic Pathway -1.28
GLYCOGEN_METABOLISM Carbohydrate Metabolism -1.26
LI_FETAL_VS_WT_KIDNEY_UP Wilm’s Tumor Signature -1.19
FATTY_ACID_METABOLISM Lipid Metabolism -1.11
b) E17.5
Up-regulated
EGF_HDMEC_UP Growth Factor Signaling 1.76
G1_TO_S_CELL_CYCLE_REACTOME Cell Cycle 1.43
WNTPATHWAY Wnt Signaling 1.35
CROONQUIST_IL6_RAS_DN JAK-STAT Pathway 1.31
HSA04010_MAPK_SIGNALING_PATHWAY MAPK Signaling 1.23
ZMPSTE24_KO_UP Ageing 1.15
HSA04520_ADHERENS_JUNCTION Cell Communication 1.13
P38MAPKPATHWAY MAPK Signaling 1.02
WILLERT_WNT_NCCIT_ALL_UP Wnt Signaling 1.43
HIF1_TARGETS Hypoxia Pathway 1.4
Down-regulated
TRYPTOPHAN_METABOLISM Amino Acid Metabolism -1.72
PROPANOATE_METABOLISM Carbohydrate Metabolism -1.38
HSA00970_AMINOACYL_TRNA_BIOSYNTHESIS Translation -1.23
VALINE_LEUCINE_AND_ISOLEUCINE_DEGRADATION Amino Acid Metabolism -1.14
HSA00564_GLYCEROPHOSPHOLIPID_METABOLISM Lipid Metabolism -1.18
GLUCONEOGENESIS Carbohydrate Metabolism -1.11
GLYCOLYSIS Carbohydrate Metabolism -1.11
NES represents the degree of enrichment of the gene set at the top or bottom of the ordered gene list.
NOM P-value measures the significance of NES for a gene set by using permutation testing. NOM P-value < 0.001 is used for table 3.
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were enriched at E14.5 in Pkd1
-/- mutants compared to
WT) as shown in Additional file 13, we identified 17
up-regulated individual genes associated with GPCR. Of
interest, genes involved in cAMP mediated signaling
and calcium regulation such as Pde4b (7.22 fold), Calcr
(6.14 fold), and Sstr2 (11.4 fold) were all up-regulated,
while negative regulator of GPCR signaling such as
Gprasp1 (59.82 fold), and Rgs3 (5.14 fold) [38] were
down-regulated. These results suggest changes in GPCR
signaling that might be associated with intracellular
cAMP and calcium regulation in the kidneys of Pkd1
-/-
animals.
Increased cAMP has been shown to promote renal
cystic epithelial proliferation in PKD [39]. We observed
up-regulation of adenylyl cyclase, Adcy7, which may
increase cAMP production in the renal cysts, which in
turn promotes renal cystic epithelial proliferation in
PKD [39]. The change in Ca
2+ homeostasis is an impor-
tant feature of ADPKD and may lead to increased levels
of cAMP [39-41]. Although the gene sets for calcium/
calcineurin/NFAT signaling were not significantly
enriched (p = 0.14), we found that Crebbp (2.08 fold),
P 2 r x 7( 1 1 . 6 6f o l d ) ,P r k c b( 2 . 5 5f o l d )a n dT r a f 2( 2 . 1 4
fold) were up-regulated in the Pkd1
-/- cystic kidneys,
suggesting a situation where limitation of intracellular
Ca
2+ could promote cAMP mediated activation of
B-Raf/MEK/ERK pathway and cellular proliferation
[39-41].
Previous studies suggested that aberrant activation of
ERK/MAPK signaling might modulate cyst growth in
ADPKD. We found three gene sets for ERK/MAPK
signaling cascades up-regulated in Pkd1
-/- kidneys com-
pared to WT at E17.5 (Table 3 and Additional file 13)
including up-regulation of Fgfr3 (10.16-fold), Map3k12
(2.32-fold), Mink1 (23.48-fold), Rps6ka5 (2.14-fold), and
Fosb (2.25-fold). Although we found slight up-regulation
of Akt1 (1.71-fold) and Eif4e (2.33-fold), no definitive
enrichment of the mTOR pathway could be determined.
This may be important from a therapeutic perspective:
the mTOR pathway has been considered as a drug tar-
get in arresting ADPKD progression, despite recent stu-
dies in humans with ADPKD that did not demonstrate a
therapeutic effect of Sirolimus and Everolimus, inhibi-
tors of the mTOR pathway, on cyst progression [42,43].
Activation of angiogenic and immune/inflammatory
pathways
Activation of immunoregulatory and inflammatory path-
ways may be involved in cyst growth in ADPKD. Multi-
p l eu p - r e g u l a t e dg e n es e t si nt h ePkd1
-/- kidneys
compared to WT at E17.5 were associated with
immune/inflammatory (JAK-STAT (n = 3), immunore-
gulation and inflammation (n = 2)) responses including
up-regulation of Il1rl1 (3.79-fold), Il28ra (2.26-fold),
Il4i1 (7.35-fold), Jakmip1 (2.6-fold) and Jakmip2 (2.57-
fold). We found increased expression of cytokines such
as Cxcl1 (2.19-fold), Cxcl16 (2.26-fold), and Clcf1 (8.57-
fold). We also found two dysregulated pathways for
aging in Pkd1
-/- kidneys compared to WT at E17.5
(Additional file 13).
Activation of HDAC inhibitor pathways
Recently it has been shown that inhibition of class I
H D A C si sa b l et os u p p r e s sPkd2 related phenotypes
[24]. Our studies have not implicated any class I
HDACs in the pathogenesis of PKD1. On the other
hand, we found down-regulation of a member of the
class II HDACs, Hdac9 (22.29-fold) in Pkd1
-/- mutants
compared to WT at E17.5. Additionally, we found mul-
tiple up-regulated gene sets belonging to the class of
histone deacetylase inhibitors (n = 7; Additional file 13)
in Pkd1
-/- kidneys compared to WT at E17.5. HDAC9
plays a role in hematopoiesis, and its deregulated
expression, along with altered expression of TGF-b2,
may be associated with human cancer and Peters’ anom-
aly [44,45]. As reported in the KEGG pathway database
(http://www.genome.jp/kegg/pathway.html), histone dea-
cetylases are involved in many pathways including signal
transduction, the notch signaling pathway, cell growth,
and death/cell cycle. Their precise role in Pkd1 depen-
dent ADPKD remains obscure. However, strong differ-
ential regulation of genes involved in the class II HDAC
regulatory cascade suggests that histone modification
may be an important event in transcriptome reprogram-
ming during PKD progression.
Comparison with other ADPKD data sets in mouse and
human
We aimed to derive correlations between the gene expres-
sion changes in PKD and a set of pathways that modulate
disease severity in our mouse model and human ADPKD.
We compared our study with another published study
using the Pkd1
L3/L3 mouse model [28] and with the data
set available on human ADPKD [29]. Chen et al. described
members of three pathways, Wnt, Notch, and BMP, as
differentially regulated in the Pkd1
L3/L3 model compared
to the control WT [28]. Our data from the Pkd1
-/- model
confirmed the differential regulation of members of these
pathways (Additional files 14 and 15). A total of 102 dysre-
gulated genes were common between the Pkd1
L3/L3 model
data and our set of differentially expressed genes at E17.5
(comparison: Pkd1
-/- mutants vs. WT), whereas 36 dysre-
gulated genes were common between our Pkd1
-/- model at
E14.5 (comparison: Pkd1
-/- mutants vs. WT) and the
Pkd1
L3/L3 model. A ~20% commonality was observed at
the pathway level between our Pkd1
-/- model and the
Pkd1
L3/L3 model. The comparison between our data set
(differentially expressed genes at E17.5) with human
ADPKD data [29] showed a 50% overlap between
Pandey et al. BMC Systems Biology 2011, 5:56
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16), which included several important pathways such as
calcium signaling, Wnt, MAPK, TGFb signaling pathways,
immune/inflammatory responses, and Notch signaling
pathways. On the individual gene level, 20% (n = 314) of
genes were similarly changed in both our mouse model
and human ADPKD (Table 4, Additional file 16).
Transcription factor analysis of Pkd1
-/- kidneys
Computational analysis of genetic regulatory regions of
co-expressed genes can furnish additional information
on the regulation of a gene set by specific transcription
factors (TFs) [29]. Using GSEA, we searched for
overrepresented TF promoter binding motifs among
differentially expressed genes (Table 1). We defined
overrepresented TF binding motifs by a NOM p-value
≤ 0.05. Additional file 17 lists all the dysregulated gene
sets with shared TF binding sites for renal develop-
ment, mitogen-mediated proliferation, cell cycle,
epithelial-mesenchymal transition, angiogenesis, and
immune/inflammatory response. Several of these
enriched transcription factors, such as Gli2 (4.39 fold),
Foxo1 (2.51 fold) and Pou2F1 (2.88 fold) were also
differentially regulated in our microarray analyses, pro-
viding additional evidence for their functional rele-
vance in PKD.
Prediction of miRNA and miRNA-target interactions, and
analysis of miRNA expression
Large scale transcriptional reprogramming during the
progression of PKD is consistent with a complex, multi-
layered regulatory process, one of the possible regulators
of which are miRNAs. Insights into the biological path-
ways potentially regulated by miRNAs in PKD were
obtained by predicting target miRNAs (Additional file 1)
using four prediction tools, TargetScan [31], miRanda
[32], miRDB [33] and microT [34] for the differentially
expressed genes in cystic kidneys at E14.5 and E17.5
(Table 5). Results were overlapped using custom written
Perl scripts (Additional file 2). Integrating the results
from several prediction algorithms helps in reducing
false positives [13]. More than two tools predicted over
5000 mRNA-miRNA interactions, which represented
approximately 500 dysregulated genes in cystic kidneys
were predicted targets of at least one miRNA. A total of
344 miRNAs were predicted to target 179 out of 454
dysregulated genes at E14.5 by different algorithms
(Table 5a and Additional file 18), whereas 372 out of
884 dysregulated genes were predicted targets of 424
miRNAs at E17.5 (Table 5b and Additional file 19). Of
these 372 and 179 dysregulated genes at E17.5 and
E14.5 respectively, about 82% were predicted targets of
multiple miRNAs (Table 5, Additional files 18 and 19),
thus suggesting a role of miRNAs in PKD transcrip-
tional reprogramming. These results are consistent with
Table 4 Top 50 differentially regulated genes common
between our mouse and human ADPKD data from Song
et al. [29]
Down-regulated Up-regulated
Gene name Mouse Human Gene name Mouse Human
Abcb4 371.51 1.90 Adcy7 2.63 2.38
Acot2 4.81 1.81 Amph 218.83 2.34
Acox2 2.70 1.97 Arhgap10 2.61 2.43
Aldh8a1 2.37 91.29 Asph 3.96 2.84
Apom 2.22 18.96 Bcat1 15.08 4.95
Apoo 4.00 2.45 Camsap1l1 10.96 2.21
Bhmt2 2.26 4.78 Ccdc109b 4.48 3.17
Casc1 10.94 2.84 Cdc42bpa 2.70 1.57
Cldn10 2.25 25.93 Eif3a 98.69 2.14
Cpn2 10.64 2.07 Emilin1 4.06 4.78
Cyp8b1 12.17 30.21 Ezh1 3.45 1.80
Dpep1 7.37 17.20 Fam98b 352.24 1.63
Enpp5 3.11 2.59 Foxp2 26.87 3.75
Enpp6 2.21 8.65 Gli2 4.39 4.29
Fam151a 3.21 6.02 Gramd1a 6.84 1.92
G6pc 11.06 4.88 Grem1 2.98 37.73
Gls 2.35 5.69 Ier2 2.67 3.25
Hgd 2.56 38.57 Jph2 39.24 1.85
Hrg 24.10 16.90 Klhl28 4.94 1.78
Itih2 6.35 2.45 Ltbp1 36.39 5.33
Kctd14 6.15 1.62 Mid1 2.59 2.51
Kng1 2.68 81.30 Nnmt 49.60 1.96
Larp5 7.00 1.57 Odf3b 13.13 1.56
Miox 28.27 20.49 Pcdh7 3.18 11.00
Napepld 2.10 2.65 Pcdh9 40.71 4.90
Napsa 3.60 10.05 Pdcl 75.38 1.71
Odz2 3.97 2.15 Pi4kb 2.90 1.75
Pck1 3.28 58.93 Pknox2 7.28 2.84
Picalm 4.93 1.71 Pml 5.69 1.65
Prap1 3.25 5.24 Pprc1 6.17 1.77
Prlr 2.31 13.73 Rab9b 55.23 2.42
Prodh2 5.34 5.45 Radil 2.92 2.18
Psen1 20.62 2.05 Rpl37 3.29 3.04
Pvalb 2.89 3.59 Sema4c 3.13 1.63
Qpct 2.34 2.20 Sept7 3.12 2.87
Rassf6 10.76 3.30 Setd7 21.09 2.57
Rgs3 5.14 2.01 Sfi1 4.63 1.67
Serpinf2 2.16 2.49 Sfxn3 14.28 2.60
Slc13a2 5.87 7.03 Slitrk5 7.02 14.33
Slc16a4 3.38 4.32 Smurf1 2.90 1.71
Slc26a7 2.82 26.10 St5 2.54 1.62
Slc2a9 4.28 11.81 Syne1 6.02 3.12
Slc4a1 3.62 2.57 Synj2 27.19 3.23
Slc5a10 8.43 11.22 Thg1l 2.91 1.69
Slc8a1 2.11 4.08 Tns1 2.66 1.75
Tbc1d4 4.20 1.66 Vps13b 6.39 1.76
Treh 2.66 2.29 Wfdc3 145.61 1.66
Trim15 235.85 1.97 Yy1 3.48 1.72
Ttr 6.52 1.93 Zbtb10 4.06 1.62
Umod 3.41 210.17 Zfhx4 2.87 4.19
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lian genes may be regulated by miRNAs [31].
Validation of expression by qPCR
Using qPCR assays for the Pkd1
-/- and WT samples, we
confirmed the microarray results on a subset of genes
that were- (i) differentially expressed on microarrays, (ii)
known/suggested to be involved in ADPKD, and (iii)
targets of miRNAs predicted by two or more tools.
These genes were P2rx7, Cpeb3, Hdac9, Sox6, Calcr,
Pitx2, Fgfr3, Fgf10, Adam22, Ddx3y, F2rl2, Grap2, Edil3,
Mysm1 and Alg6 (Figures 5 and6). Qualitatively, the
qPCR validation data agreed with the microarray data
(Additional file 20). On the other hand, we found that
for certain genes such as Adam22, Grap2 and F2rl2 the
fold changes observed on microarrays varied from those
obtained by qPCR (Additional file 20). Several factors
may be responsible for these variations, among which
include the distinct platforms used for microarrays and
qPCR, differences in qPCR amplicon/primers and hybri-
dization probes, non-specific and cross-hybridization
and issues associated with amplification of mRNA sam-
ples [46,47].
Computational identification of a large number of
miRNA-mRNA target interactions suggested that the
expression of miRNAs might also change during the
progression of PKD. We tested this hypothesis by deter-
mining the differential expression of 9 miRNAs (mmu-
miR-10a, mmu-miR-30a-5p, mmu-miR-96, mmu-miR-
126-5p, mmu-miR-182, mmu-miR-200a, mmu-miR-204,
mmu-miR-429, and mmu-miR-488) between WT and
Pkd1
-/- genotypes at E14.5 and E17.5 (Figures 7 and8).
These nine miRNAs are expressed in kidney [48], but
have not been previously associated with ADPKD. In our
computational analysis, two or more tools predicted
them as targets for differentially expressed genes at E14.5
and E17.5. The significance of changes in relative expres-
sion of miRNAs among the two groups was tested by
Student’s t-test, and a cutoff of 1.2 fold [49] and P ≤ 0.05
was used to determine the differential miRNA
accumulation.
Among the 9 miRNAs tested at E14.5, only two miR-
NAs, miR-488 and miR-204, were down-regulated in
Pkd1
-/- kidneys compared to WT, miR-96 did not change,
and the remaining 6 miRNAs were up-regulated in
Pkd1
-/- kidneys compared to WT (Figure 7). In contrast,
at E17.5 miR-96, miR-182 and miR-30a were up-regu-
lated in Pkd1
-/- kidneys compared to WT. miR-200a did
not show significant variation between the WT and
Pkd1
-/- kidneys at E17.5 (Figure 8). This indicates that
miRNA expression also undergoes reprogramming dur-
ing PKD. Given that renal cystic- and control- kidneys
contained a mixture of cell types, the moderate effects we
observed in changes in miRNA levels may in reality be
far stronger in specific cell/tissue types.
miRNA-mRNA interactions
Most miRNAs negatively regulate the levels of expres-
sion of their targets: therefore, miRNA-mRNA target
pair should be inversely correlated for their expression
levels i.e. if the expression of a given miRNA is up-regu-
lated, levels of its target genes should be down-regulated
and vice-versa. Indeed, this was observed for a large
number of predicted miRNA:mRNA interactions. At
E14.5, expression of 9 miRNAs was inversely related to
expression of 46 potential target genes, indicating that
these relationships may be functional miRNA-target
combinations in ADPKD (Additional file 21). Similarly,
7 8g e n e st h a tw e r ep o t e n t i a lt a r g e t so f9m i R N A sw e r e
inversely related by their expression at E17.5 (Additional
file 21). Several of the genes verified with qPCRs
(Figures 56), and predicted as targets of the miRNAs,
showed a reciprocal relationship (Table 6). For example,
down-regulation of miR-200a at E17.5 was correlated
with up-regulation of Pitx2 in the Pkd1
-/- mutants
(Additional file 21). Similarly, down-regulation of miR-
10a, miR-126-5p, miR-204, and miR-488 at E17.5 were
inversely correlated with up-regulation of Ltbp1, Edil3,
Table 5 Target miRNA prediction for significantly regulated genes at (a) E14.5 and (b) E17.5
(a) E14.5 miRanda miRDB TargetScan 1348 miR-gene TargetScan and miRDB
microT 1329 miR-gene 187 miR-gene 52 miR-gene 10 miR-gene 4 miR-gene
miRanda 11350 miR-gene - 809 miR-gene 336 miR-gene 104 miR-gene
miRDB 2009 miR-gene - - 137 miR-gene -
microT and miRanda - 37 miR-gene 8 miR-gene 4 miR-gene
(b) E17.5 miRanda miRDB TargetScan 3229 miR-gene TargetScan and miRDB
microT 2478 miR-gene 504 miR-gene 118 miR-gene 30 miR-gene 4 miR-gene
miRanda 25540 miR-gene - 2114 miR-gene 892 miR-gene 269 miR-gene
miRDB 4492 miR-gene - - 331 miR-gene -
microT and miRanda - 82 miR-gene 20 miR-gene 4 miR-gene
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Figure 5 qPCR analysis of mRNAs in PKD at embryonic age 14. Expression of 12 genes (Ddx3y, Adam22, Cpeb3, Sox6, Edil3, Mysm1, Pitx2,
F2rl2, Grap2, P2rx7, Fgfr3 and Fgf10) significantly regulated on mRNA microarray was verified using qPCR assays. Ddx3y, Adam22, Cpeb3, Sox6 and
Edil3 were down-regulated in Pkd1
-/- kidneys. Mysm1, Pitx2, F2rl2, Grap2, P2rx7, Fgfr3 and Fgf10 were up-regulated in Pkd1
-/- kidneys. ‘*’ significantly
different at p-value < 0.05.
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Figure 6 qPCR analysis of mRNAs in PKD at embryonic age 17. Expression of 9 genes (Alg6, Cpeb3, Edil3, Hdac9, Sox6, Ltbp1, Fgfr3, P2rx7 and
Pitx2) significantly regulated on mRNA microarray was verified using qPCR assays. (A) Alg6, Cpeb3, Edil3, Hdac9 and Sox6 were down-regulated in
Pkd1
-/- kidneys whereas Ltbp1, Fgfr3, P2rx7 and Pitx2 were up-regulated (B) in Pkd1
-/- kidneys. ‘*’ significantly different at p-value < 0.05.
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Figure 7 qPCR analysis of miRNAs in PKD at embryonic age 14. Expression of 9 miRNAs (miR-204, miR-488, miR10a, miR-30a, miR-96, miR-
126-5p, miR-182, miR-200a and miR-429), predicted to target significantly regulated genes at E14.5 was assayed using miRNA-qPCR. miR-204 and
miR-488 (A) were down-regulated in Pkd1
-/- kidneys whereas miR10a, miR-30a, miR-96, miR-126-5p, miR-182, miR-200a and miR-429 (B) were up-
regulated in Pkd1
-/- kidneys. ‘*’ significantly different at p-value < 0.05.
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Figure 8 qPCR analysis of miRNAs in PKD at embryonic age 17. Expression of 9 miRNAs (miR-10a, miR-126-5p, miR-200a, miR-204, miR-429,
miR-488, miR-96, miR-182 and miR-30a-5p), predicted to target significantly regulated genes at E17.5 was evaluated using miRNA-qPCR assays.
(A) miR-10a, miR-126-5p, miR-200a, miR-204 and miR-429 were down-regulated in Pkd1
-/- kidneys. (B) miR-488, miR-96, miR-182 and miR-30a-5p
were up-regulated in Pkd1
-/- kidneys. ‘*’ significantly different at p-value < 0.05.
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Page 15 of 23P2rx7, and Fgfr3 respectively (Additional file 21). Con-
versely, we found that up-regulation of miR-30a-5p,
miR-96 and miR-182 at E17.5, and miR-429 at E14.5
were reciprocally correlated with down-regulation of
Cpeb3, Sox6, Hdac9, and Ddx3y respectively in Pkd1
-/-
mutants (Additional file 21). Moreover, miRs-10a, -30a-
5p, -96, -126-5p, -182, -200a, -204, -429, and -488 have
not been previously linked to PKD. Thus, our analysis
suggests a potential important role for miRNAs in PKD,
though we emphasize that these predicted miRNA:
mRNA interaction pairs are subject to further experi-
mental validation.
We analyzed the functional enrichment of predicted and
validated (by qPCR) miRNAs for differentially expressed
genes in each comparison in an attempt to uncover the
functional meaning among these miRNAs (Figure 9).
Genes that were commonly targeted by the differentially
expressed miRNAs in Pkd1
-/- samples were clustered in
18 biochemical pathways. The overall analysis high-
lighted that signal transduction pathways such as
Table 6 Selected inverse gene-(predicted)miRNA relations
Genes Fold Change
gene (E14.5)
on microarray
Fold Change
Gene (E17.5)
on microarray
Target miRNA Fold Change
miRNA (E14.5)
from qPCR
Fold Change
miRNA (E17.5)
from qPCR
Prediction
Algorithms
Pathways
Adam22 -133 miR-30a-5p 1.70 1.31 TargetScan, miRanda Cell-matrix interaction
Calcr 4.63 6.14 miR-200a 1.36 -1.10 TargetScan, miRanda
and miRDB;
TargetScan, miRanda
Neuroactive ligand-
receptor interaction
Calcr 4.63 6.14 miR-10a 1.26 -1.23 TargetScan, miRanda
and miRDB;
TargetScan, miRanda
Neuroactive ligand-
receptor interaction
Cpeb3 -19.88 -6.47 miR-30a-5p 1.70 1.31 TargetScan, miRanda
Cpeb3 -19.88 -6.47 miR-200a 1.36 -1.10 TargetScan, miRanda
Ddx3y -13 miR-429 1.27 -1.17 TargetScan, miRanda
and miRDB
RIG-I-like receptor
signaling pathway
Edil3 -4.82 -6.43 miR-126-5p 1.43 -1.45 TargetScan, miRanda
and miRDB
Cell adhesion
Edil3 -4.82 -6.43 miR-182 1.62 1.48 TargetScan, miRanda
and miRDB
Cell adhesion
F2rl2 35.26 miR-126-5p 1.43 -1.45 TargetScan, miRDB
Fgf10 1.05 4.18 miR-126-5p 1.43 -1.45 TargetScan, miRanda
and miRDB; miRDB
and miRanda
MAPK signaling
Fgfr3 4.12 10.16 miR-488 -2.03 2.11 TargetScan, miRanda
and miRDB
MAPK signaling
Grap2 157 miR-10a 1.26 -1.23 TargetScan, miRanda T cell receptor signaling
pathway
Hdac9 -1.54 -22.29 miR-30a-5p 1.70 1.31 TargetScan, miRanda;
TargetScan, miRanda
and miRDB
Notch signaling
Hdac9 -1.54 -22.29 miR-204 -1.32 -1.22 TargetScan, miRanda;
TargetScan, miRanda
and miRDB
Notch signaling
Hdac9 -1.54 -22.29 miR-182 1.62 1.48 TargetScan, miRanda;
TargetScan, miRanda
and miRDB
Notch signaling
Ltbp1 -368.46 36.38 miR-10a 1.26 -1.23 TargetScan, miRanda TGF-Beta signaling
Mysm1 2.85 3.24 miR-126-5p 1.43 -1.45 TargetScan, miRanda
P2rx7 4.65 11.66 miR-204 -1.32 -1.22 miRDB, miRanda Calcium Signaling
Pitx2 1.23 3.91 miR-200a 1.36 -1.10 TargetScan, miRanda
and miRDB
TGF-Beta signaling
Sox6 -1.94 -28.68 miR-96 1.15 1.76 TargetScan, miRanda
and miRDB;
TargetScan, miRanda
Negative regulation of
transcription
Sox6 -1.94 -28.68 miR-182 1.62 1.48 TargetScan, miRanda
and miRDB;
TargetScan, miRanda
Negative regulation of
transcription
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Page 16 of 23calcium, VEGF, Notch, and MAPK signaling (Figure 9)
may be regulated by miRNA. For example, miR-30a-5p
may be involved in histone deactylase inhibitor path-
ways, apoptosis, calcium and Wnt signaling (Figure 9);
miR-10a may be involved in TGF-b and hedgehog sig-
naling; miR-204 may be involved in calcium signaling
w h i l em i R - 4 8 8m a yb ei n v o l v e di nM A P Ks i g n a l i n gb y
targeting Fgfr3 (Figure 9). Thus, we generated a compre-
hensive atlas of miRNA-target genes and pathways dur-
ing the progression of PKD. This dataset will serve as a
useful resource for future investigations.
Discussion
In the current investigation, we have attempted to
uncover the gene expression signatures associated with
the initiation and progression of ADPKD, to decipher the
signal transduction pathways associated with these
changes in gene expression, and to explore the potential
role of miRNAs in effecting these gene expression and
signal transduction differences between normal and PKD
kidneys. We used a combinatorial approach involving
microarrays, data mining and prediction of target miR-
NAs to profile changes in gene expression during pro-
gression of ADPKD, integrate various signaling pathways
and present a possible cellular signaling circuitry in PKD
(Figure 10). In parallel to the mRNA expression profiling,
we also determined the changes in expression of several
miRNAs that were computationally identified for their
probable roles in ADPKD, thus allowing us to predict
several miRNA-mRNA reciprocal interactions. By com-
paring our datasets with those available for human
ADPKD, we found common mis-regulated pathways in
the developmental and signaling pathways. Identification
of commonly regulated pathways and genes between
miR126-5p
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Figure 9 Overrepresented miRNA regulatory pathways in PKD. Gene Ontology and Gene Set Enrichment Analysis were used to identify
significant enrichment for pathway annotations among differentially expressed target genes of predicted miRNAs in PKD. The figure shows each
miRNA targets more than one pathway and each pathway is targeted by more than one miRNA. Only miRNAs validated by qPCR are shown.
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Page 17 of 23mice and humans is essential for designing effective ther-
apeutics, as these genes/pathways would be targets for
pharmacological intervention in humans with PKD.
Transcriptome changes in PKD
A high level of complexity in the molecular pathobiology
was found in Pkd1
-/- cystic kidneys. We identified genes
that were changed only in Pkd1
-/- animals such as Aqp7,
Bmp6, Bmp8b, Ddx3y, Kl, Psen1 and Pitx2. This shows
changes in expression of developmental and nephron-
segment specific genes. Further we identified changes in
expression of genes that may be associated with pre-cys-
tic stages leading to cyst formation such as changes in
the components of Wnt signaling. We identified changes
in gene expression related to cyst growth such as compo-
nents of MAPK (e.g. Map3k12, Fgf10, Prkcb, Traf2) and
TGF-b (e.g. Pitx2) signaling that were up-regulated in the
Pkd1
-/- animals. The GO term enrichment and GSEA
revealed changes in calcium, MAPK, Wnt, TGF-b and
JAK/STAT signaling pathways in the Pkd1
-/- animals.
Additionally, this analysis showed that the class II
HDAC, Hdac9 was strongly down-regulated in Pkd1
-/-
animals. This could effect more global changes in gene
expression.
Mitogen-Activated Protein Kinases play central roles in
the signal transduction pathways that affect gene expres-
sion, cell proliferation, differentiation and apoptosis [50].
Although some studies have suggested that cellular pro-
liferation may be involved in initial cyst formation in
PKD, other evidence suggests that abnormal proliferation
contributes to cyst growth rather than cyst initiation
[51-54]. Our data (Table 3 and Additional file 6), showing
a greater increase in MAPK-associated pathways at E17.5
as compared with E14.5, are more consistent with the lat-
ter hypothesis that proliferation is more important in cyst
growth than in initiation.
Wnt signaling in ADPKD
Previous studies have shown that the activation of cano-
nical Wnt signaling [55] and inhibition of non-canonical
Wnt signaling (such as decreased activation of c-jun
N-terminal kinase, JNK, and transient changes in intra-
cellular Ca
2+ concentrations) may play roles in cyst for-
mation in PKD [56]. We found Wnt7b (1.6 fold), Fzd6
(1.3 fold), Dvl3 (1.6 fold) and Lef1 (1.7 fold) were up-
regulated while Apc (2.4 fold), an inhibitor of canonical
Wnt signaling was down-regulated at E14.5. Although
microarray probes failed to detect increased Wnt7a
Figure 10 Schematic summary of dysregulated signalling pathways in Pkd1
-/- model. The figure shows aberrant change in signalling
pathways in Pkd1
-/- mouse model. Up-regulated genes are shown in red and down-regulated genes in green. Genes that were not differentially
expressed are shown in black. Circles designate chemical compounds and DAG stands for diacylglycerol.
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tion of Wnt7a in Pkd1
-/- animals (Qin et al, submitted).
Moreover, in a study of Pkd1
L3/L3 mouse model Wnt7a
and Wnt7b were also found up-regulated in mutant kid-
neys [28]. The GSEA results also showed enrichment of
canonical Wnt signaling for up-regulated genes in Pkd1
-/-
mutants at E14.5 (Table 3). Canonical Wnt signaling was
also up-regulated at E17.5, as determined by both GO
analysis and GSEA (Tables 2 and 3, Additional files 12
and 13). Together, these results suggested that there may
be an increase in canonical Wnt signaling in Pkd1
-/- ani-
mals. Additionally, the GO term enrichment analysis
showed down-regulation of non-canonical Wnt signaling
in Pkd1
-/- animals at E14.5 (Table 2, Additional file 12).
In contradistinction to the GO and GSEA analyses
suggesting increased Wnt signaling in Pkd1
-/- kidneys,
we found that two potential inhibitors of Wnt signaling,
Cer1 and Frzb (respectively increased 12 fold and 9.7
fold at E14.5), were up-regulated in Pkd1
-/- animals at
E14.5. Cer1 and Frzb belong to the family of sFRPs
(secreted Frizzled Related Proteins) that act as inhibitors
of Wnt signaling in animals such as Xenopus and chick
by interfering with the binding of Wnt proteins to
Frizzled transmembrane receptors [57]. Frzb is a known
Wnt antagonist in mammals [57,58]. However the
mouse Cer1 may not inhibit Wnt signaling [59]. At pre-
s e n tw ea r eu n a b l et oe x p l a i nt h ed i s c r e p a n c yb e t w e e n
the overall informatic result that canonical Wnt signal-
ing is increased in Pkd1
-/- kidneys, and the observed
increased expression of Wnt antagonists Cer1 and Frzb.
It is possible that Cer1 and/or Frzb have a greater ability
to interfere with non-canonical vs. canonical Wnt sig-
naling, and that this will be borne out by future studies.
Calcium signaling in ADPKD
The polycystin-1/2 complex (PC1/PC2) mediates Ca
2+
entry into the cell in response to mechanical stimulation
of the primary cilium [60]. This in turn triggers addi-
tional release of Ca
2+ from intracellular stores. Thus,
disruption of the polycystin pathway alters intracellular
Ca
2+ homeostasis [1,56]. It has been suggested that
altered intracellular Ca
2+ levels increases cAMP levels
by stimulating adenylyl cyclases [60]. In turn, increased
cAMP paradoxically stimulates MAPK/ERK signaling
and promotes renal cystic epithelial proliferation in
Pkd1
-/- cells [39]. Our results showed that in Pkd1
-/- ani-
mals at E17.5 an adenylyl cyclase, Adcy7 was up-regu-
lated. Thus, increased gene expression of an adenylyl
cyclase may be an additional contributing factor to
increased cAMP levels in ADPKD.
Novel regulatory mechanisms in ADPKD
Our study identifies several new nodes of regulation in
ADPKD. For example, we found a strong down-
regulation of Alg6 (asparagine-linked glycosylation 6
homolog) in the Pkd1
-/- genotype at E17.5. ALGs are
important components of the glycosylation pathway
involving the endoplasmic reticulum (ER) and the Golgi
apparatus. Alg6 encodes a member of the glucosyltrans-
ferase family that catalyzes the addition of the first glu-
cose residue to the growing lipid-linked oligosaccharide
precursor of N-linked glycosylation. Mutations in this
gene are associated with congenital disorders of glycosy-
lation type Ic [61]. Indeed, in Pkd1
-/- mice, defective gly-
cosylation of protein has been observed, that may have
important implications for ADPKD [62,63]. As Alg6
encodes an ER glucosyltransferase [64], its specific
downregulation in the Pkd1
-/- genotype indicates meta-
bolic reprogramming in the ER and Golgi complex.
Thus, exploring Alg6 function in knock-down studies in
kidneys may provide new insights regarding the disease
processes underlying ADPKD.
The comparison of the Pkd1
-/-mouse model and
human ADPKD data sets revealed significant overlaps.
Some representative of commonly up-regulated genes
include Adcy7 (Calcium signaling), Crebbp (Wnt, Jak-
STAT, calcium, TGFb signaling), Cxcl1 (Jak-STAT sig-
naling), Vegfb (VEGF signaling), Dvl2 (Wnt signaling),
Tgif1 and Smurf1 (TGFb signaling). Representative
down-regulated genes that were commonly changed
between the two data sets include Umod (loop of Henle
marker), Rgs3 (GPCR signaling), Pvalb (distal tubule
marker), Pck1 (proximal tubule marker), and Lamc3
(Focal adhesion). Thus, these genes may be used as
prognostic markers for ADPKD.
Possible regulatory roles of miRNAs in ADPKD
We examined the possible involvement of miRNAs in
ADPKD in the Pkd1
-/- mouse model. While several miR-
NAs can target a single transcript, each miRNA can also
have multiple targets [13,31]. Thus, moderate alterations
in miRNA levels can have profound effects on the accu-
mulation of their targets [65,66]. However, their role in
ADPKD, both at the individual as well as the systems
levels, is still under investigation, as only three studies
have directly demonstrated changes in miRNA expres-
sion in ADPKD [18,22,23]. We have addressed this pro-
blem by systemically estimating the possible miRNAs
that may target genes deregulated during disease pro-
gression (Additional file 1). We have predicted and veri-
fied (by qRT-PCR) reciprocal expression of several
miRNAs and their predicted targets in Pkd1
-/- animals
(Table 6). We observed that miRNAs: miRs-10a, -30a-
5p, -96, -126-5p, -182, -200a, -204, -429, and -488; and
the miRNA-mRNA interactions such as miR-126-5p-
Fgf10, miR-488-Fgfr3, miR-182-Hdac9, miR-204-P2rx7
and miR-96-Sox6 (as shown in Table 6) have not been
previously reported in ADPKD.
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mediated regulation, as their components require finely
tuned temporal changes in their expression [65,67].
miRNAs may affect the responsiveness of cells to signal-
ing molecules such as TGFb,W n t ,N o t c h ,a n de p i d e r -
mal growth factor [67]. Once a miRNA targets an
inhibitor of a signaling cascade, it serves as a positive
regulator by either amplifying signal strength or dura-
tion, or empowering cell responsiveness to otherwise
sub-threshold stimuli. For example, miR-126 promotes
angiogenesis and vascular integrity [68] by inhibiting the
production of natural repressor (SPRED1 and PIK3R2)
of VEGF signaling, suggesting that it may serve as an
effective target for anti-angiogenic therapies. We found
that miR-126-5p may be involved in calcium, EGF,
MAPK signaling, and neuroactive ligand-receptor inter-
action (Figure 9; Additional file 21). Previous studies
[13,65,67] have shown that a single miRNA can act
simultaneously on multiple signaling pathways to coor-
dinate their biological effects and concurrently several
miRNAs may regulate single pathway (Figure 9). More-
over, the predicted miRNA:mRNA interactions sug-
gested that the involvement of miRNAs in the signaling
pathways through their target mRNAs may lead to the
dysregulation of these pathways. For example, the inter-
action of miR-204:P2rx7 (Figure 10) suggested a possibi-
lity that the down-regulation of miR-204 may lead to
up-regulation of its target gene, P2rx7 at E17.5 in
Pkd1
-/- kidneys. P2rx7 is a cell-surface, ligand-gated
cation channel and its stimulation leads to alteration in
the intracellular Ca
2+ levels that may further result into
dysregulation of calcium signaling. Therefore, by target-
ing P2rx7, miR-204 may disrupt calcium signaling. Simi-
larly, at E17.5 in Pkd1
-/- animals, the up-regulation of
Fgfr3 and Fgf10 (components of MAPK signaling) and
down-regulation of their target miRNAs- miR-488 and
miR-126-5p respectively, may stimulate MAPK signaling
and cell proliferation in Pkd1
-/- samples.
The functional correlation between the differentially
expressed mRNAs and miRNAs as a module in ADPKD
revealed a tight post-transcriptional regulatory network
at the mRNA level whose alteration might contribute to
increased immune response, by either direct miRNA tar-
geting or through secondary proteins. Further progress
in the understanding of miRNA activity, the identifica-
tion of miRNA signatures in different states, and the
advancement of miRNA manipulation techniques will be
valuable for deciphering the roles of individual miRNAs
in PKD. The overall discovery of differentially regulated
miRNAs in the different diseases is expected not only to
broaden our biological understanding of these diseases,
but more importantly, to identify candidate miRNAs as
potential targets for future clinical applications.
Conclusion
We have attempted to reveal the molecular players of
PKD in a Pkd1
-/- mouse model. Taken together, our
study suggests the presence of complex layers of regula-
tion in ADPKD. Our microarray data revealed genes
that specifically changed during disease condition.
Further we identified genes related to pre-cystic stages
and cyst progression. Our model suggests a cascade of
signaling events involving up-regulation of canonical-
and down-regulation of non-canonical- Wnt signaling
that may result in decreased intracellular Ca
2+ concen-
tration, resulting in an increase of intracellular cAMP
levels that in turn stimulates MAPK/ERK signaling lead-
ing to proliferation, followed by increased Jak-STAT sig-
naling and inflammation (Figure 10), ultimately leading
to renal failure. Further, we determined gene expression
signatures common between the Pkd1
-/- mouse model
and human ADPKD. These could be used as prognostic
markers of disease progression in PKD. Moreover, we
add various new components including Alg6, Hdac9 and
several miRNAs to the regulatory layers of ADPKD. We
predicted that several of the differentially regulated
genes are miRNA targets and miRs-10a, -30a-5p, -96,
-126-5p, -182, -200a, -204, -429, and -488 may be
important players in cellular signalling events leading to
PKD. Furthermore, it is interesting to note that these
miRNAs have not been previously reported in PKD. It
has been proposed that a single miRNA can target more
than hundred genes and one ge n ec a nb et h et a r g e to f
several miRNAs [69,70]. A future challenge will be to
systemically identify all of the miRNAs affecting, and
regulated by, the dysregulated cell signalling pathways in
ADPKD. Extensive functional analyses of these miRNAs
and their target genes by performing knockout and
over-expression studies, individually and in combination,
are likely to open up new avenues for PKD research.
Additional material
Additional file 1: Schematic representation of target miRNA
prediction for significantly regulated genes. Step-wise approaches
used to predict target miRNAs for the significantly regulated genes
obtained at three comparisons, shown in Additional file 1. We used four
prediction tools- TargetScan, miRanda, miRDB and microT and the results
obtained from individual tool were overlapped by custom written Perl
scripts. Only those miRNA-mRNA pairs were considered for further study
that were predicted by atleast two tools.
Additional file 2: Perl script used for integrating prediction tools
results. Perl script used for integrating prediction tools results
Additional file 3: Gene-primers used for qPCR. This table shows list of
primers used for qPCR analysis of genes
Additional file 4: Design of experiment. This figure shows the
experimental design implied in this study. It shows four comparisons
including two stages-E14.5 and E17.5 and two genotypes- Pkd1
-/- and
wild-type.
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Page 20 of 23Additional file 5: Significantly regulated genes at E14.5. This table
shows the significantly regulated genes obtained for mutant versus wild-
type comparison at E14.5
Additional file 6: Significantly regulated genes at E17.5. This table
shows the significantly regulated genes obtained for mutant versus wild-
type comparison at E17.5
Additional file 7: Significantly regulated genes in wild-types across
time points E14.5 to E17.5. This table shows the significantly regulated
genes obtained for wild-types when compared at E14.5 and E17.5
Additional file 8: Significantly regulated genes in mutants across
time points E14.5 to E17.5. This table shows the significantly regulated
genes obtained for mutant when compared at E14.5 and E17.5
Additional file 9: Significantly regulated genes specific for disease
transition. This table shows the significantly regulated genes that are
specific for transition under disease condition.
Additional file 10: Significantly regulated genes specific for healthy
transition. This table shows the significantly regulated genes that are
specific for transition under healthy condition.
Additional file 11: Significantly regulated genes specific to aging.
This table shows the significantly regulated genes that are specific for
aging and common to both diseased and healthy conditions.
Additional file 12: Gene Ontology terms- overrepresented biological
processes. This table shows the overrepresented Biological Processes
from Gene ontology for significantly regulated genes. Sheets 1 through 3
show overrepresented biological processes for up- and down-regulated
genes obtained for E14.5 mutant versus wild-type comparison, E17.5
mutant versus wild-type, and mutants at E14.5 versus E17.5.
Additional file 13: Gene Set Enrichment Analysis- overrepresented
gene sets or pathways. This table shows the overrepresented gene-
sets/pathways obtained from Gene Set Enrichment Analysis for
significantly regulated genes. Sheets 1 through 3 show overrepresented
gene-sets for up- and down-regulated genes obtained for E14.5 mutant
versus wild-type comparison, E17.5 mutant versus wild-type, and mutants
at E14.5 versus E17.5.
Additional file 14: Common genes obtained between Pkd1
L3/L3 and
Pkd1
-/- mouse models. This figure shows some of the early and late
responsive genes we obtained in comparison between Pkd1
L3/L3 and
Pkd1
-/- mouse models.
Additional file 15: Common genes in Pkd1
L3/L3 and Pkd1
-/- mouse
models. This table shows the common genes and pathways obtained
from comparing the Pkd1
L3/L3 and Pkd1
-/- mouse models.
Additional file 16: Common genes in Pkd1
-/- mouse model and
human ADPKD. This table shows the common genes and pathways
obtained from comparing the Pkd1
-/- mouse model and human ADPKD.
Additional file 17: Gene Set Enrichment Analysis- overrepresented
gene sets with shared Transcription Factors. This table shows the
overrepresented overrepresented gene sets with shared Transcription
Factors obtained from Gene Set Enrichment Analysis for significantly
regulated genes. Sheets 1 through 3 show overrepresented gene-sets
with shared Transcription Factors for up- and down-regulated genes
obtained for E14.5 mutant versus wild-type comparison, E17.5 mutant
versus wild-type, and mutants at E14.5 versus E17.5.
Additional file 18: Predicted target miRNAs for significantly
regulated genes at E14.5. This table shows the predicted target
miRNAs for significantly regulated genes at E14.5. Four tools-TargetScan,
miRanda, miRDB and microT were used for prediction and results were
overlapped. Only those miRNA:gene pairs are shown that are predicted
by atleast two tools.
Additional file 19: Predicted target miRNAs for significantly
regulated genes at E17.5. This table shows the predicted target
miRNAs for significantly regulated genes at E17.5. Four tools-TargetScan,
miRanda, miRDB and microT were used for prediction and results were
overlapped. Only those miRNA:gene pairs are shown that are predicted
by atleast two tools.
Additional file 20: Comparison of microarrays and qPCR results. This
table shows the fold change obtained from both microarrays and qPCR
for significantly regulated genes (that were validated by qPCR).
Additional file 21: miRNA:target inverse relationship. This table
shows the predicted miRNA:mRNA inverse relationship for significantly
regulated genes and 9 selected miRNAs. The expression of these nine
miRNAs was validated by qPCR. Only those miRNA:mRNA pairs are
shown that are predicted by atleast two tools and show inverse
correlation to each other.
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